Merck buys a fledgling neurodegenerative biotech spawned by an old GSK discovery alliance. What’s up with that?
Avalon Ventures chief Jay Lichter has a well-known yen for drug development programs picked up in academia. And what he found in Haoxing Xu’s lab …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
